IL289039A - Prostate-specific membrane antigen (psma) ligands and their uses - Google Patents
Prostate-specific membrane antigen (psma) ligands and their usesInfo
- Publication number
- IL289039A IL289039A IL289039A IL28903921A IL289039A IL 289039 A IL289039 A IL 289039A IL 289039 A IL289039 A IL 289039A IL 28903921 A IL28903921 A IL 28903921A IL 289039 A IL289039 A IL 289039A
- Authority
- IL
- Israel
- Prior art keywords
- psma
- ligands
- prostate specific
- specific membrane
- membrane antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184015 | 2019-07-02 | ||
| PCT/EP2020/068386 WO2021001360A1 (en) | 2019-07-02 | 2020-06-30 | Prostate specific membrane antigen (psma) ligands and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL289039A true IL289039A (en) | 2022-02-01 |
Family
ID=67145647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289039A IL289039A (en) | 2019-07-02 | 2021-12-15 | Prostate-specific membrane antigen (psma) ligands and their uses |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230226227A1 (enExample) |
| EP (1) | EP3993837A1 (enExample) |
| JP (2) | JP7805170B2 (enExample) |
| KR (1) | KR20220044496A (enExample) |
| CN (3) | CN120441497A (enExample) |
| AR (1) | AR119331A1 (enExample) |
| AU (3) | AU2020299974A1 (enExample) |
| BR (1) | BR112021026812A2 (enExample) |
| CA (1) | CA3144557A1 (enExample) |
| CL (1) | CL2021003525A1 (enExample) |
| CO (1) | CO2021017708A2 (enExample) |
| IL (1) | IL289039A (enExample) |
| MX (1) | MX2022000136A (enExample) |
| PH (1) | PH12021553284A1 (enExample) |
| TW (1) | TW202114742A (enExample) |
| WO (1) | WO2021001360A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021219719A1 (en) * | 2020-04-29 | 2021-11-04 | Advanced Accelerator Applications (Italy) Srl | Methods for radiolabelling psma binding ligands and their kits |
| CN121604981A (zh) | 2023-07-21 | 2026-03-03 | 诺华公司 | 靶向psma的放射性配体治疗方案 |
| WO2025125469A1 (en) | 2023-12-13 | 2025-06-19 | Swiss Rockets Ag | Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271026A1 (en) | 2000-07-11 | 2002-01-21 | Bml, Inc. | Remedies for bone diseases |
| HUE045028T2 (hu) * | 2011-08-05 | 2019-12-30 | Molecular Insight Pharm Inc | Radiojelzett prosztataspecifikus membrán antigén inhibitorok |
| GEP20237479B (en) * | 2013-10-18 | 2023-03-27 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| KR20250057132A (ko) | 2016-03-22 | 2025-04-28 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| US11478558B2 (en) * | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| IL276528B2 (en) * | 2018-02-06 | 2024-11-01 | Univ Johns Hopkins | PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy |
| WO2020028323A1 (en) * | 2018-07-30 | 2020-02-06 | The Johns Hopkins Universtiy | Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
-
2020
- 2020-06-30 MX MX2022000136A patent/MX2022000136A/es unknown
- 2020-06-30 JP JP2021578240A patent/JP7805170B2/ja active Active
- 2020-06-30 PH PH1/2021/553284A patent/PH12021553284A1/en unknown
- 2020-06-30 US US17/622,060 patent/US20230226227A1/en active Pending
- 2020-06-30 EP EP20734426.8A patent/EP3993837A1/en active Pending
- 2020-06-30 WO PCT/EP2020/068386 patent/WO2021001360A1/en not_active Ceased
- 2020-06-30 CA CA3144557A patent/CA3144557A1/en active Pending
- 2020-06-30 KR KR1020227003148A patent/KR20220044496A/ko active Pending
- 2020-06-30 AU AU2020299974A patent/AU2020299974A1/en not_active Abandoned
- 2020-06-30 CN CN202510573851.3A patent/CN120441497A/zh active Pending
- 2020-06-30 CN CN202080047295.1A patent/CN114341118A/zh active Pending
- 2020-06-30 CN CN202510573926.8A patent/CN120441498A/zh active Pending
- 2020-06-30 BR BR112021026812A patent/BR112021026812A2/pt unknown
- 2020-07-01 AR ARP200101868A patent/AR119331A1/es unknown
- 2020-07-02 TW TW109122386A patent/TW202114742A/zh unknown
-
2021
- 2021-12-15 IL IL289039A patent/IL289039A/en unknown
- 2021-12-23 CO CONC2021/0017708A patent/CO2021017708A2/es unknown
- 2021-12-28 CL CL2021003525A patent/CL2021003525A1/es unknown
-
2024
- 2024-02-09 AU AU2024200850A patent/AU2024200850B2/en active Active
-
2025
- 2025-07-17 JP JP2025120662A patent/JP2025165975A/ja active Pending
- 2025-11-24 AU AU2025271182A patent/AU2025271182A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553284A1 (en) | 2022-08-01 |
| JP2025165975A (ja) | 2025-11-05 |
| CO2021017708A2 (es) | 2022-05-20 |
| BR112021026812A2 (pt) | 2022-02-22 |
| CN120441497A (zh) | 2025-08-08 |
| WO2021001360A1 (en) | 2021-01-07 |
| EP3993837A1 (en) | 2022-05-11 |
| JP2022538478A (ja) | 2022-09-02 |
| MX2022000136A (es) | 2022-04-27 |
| AU2020299974A1 (en) | 2022-01-27 |
| AR119331A1 (es) | 2021-12-09 |
| TW202114742A (zh) | 2021-04-16 |
| US20230226227A1 (en) | 2023-07-20 |
| AU2024200850A1 (en) | 2024-02-29 |
| CN114341118A (zh) | 2022-04-12 |
| AU2024200850B2 (en) | 2025-09-04 |
| CN120441498A (zh) | 2025-08-08 |
| KR20220044496A (ko) | 2022-04-08 |
| AU2025271182A1 (en) | 2025-12-18 |
| CA3144557A1 (en) | 2021-01-07 |
| JP7805170B2 (ja) | 2026-01-23 |
| CL2021003525A1 (es) | 2022-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266800A (en) | Prostate-specific membrane antigen-binding protein | |
| IL255424B (en) | Prostate-specific membrane antigen bispecific binding agents and uses thereof | |
| MX2021006235A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| MX2024000742A (es) | Anticuerpos anti-tigit. | |
| IL291299A (en) | Anti-TNFR2 antibodies, preparations containing them and their uses | |
| AU2016258174B2 (en) | Prostate specific membrane antigen binding fibronectin type III domains | |
| PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| ZA201804601B (en) | Psma binding antibody and uses thereof | |
| IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
| IL289039A (en) | Prostate-specific membrane antigen (psma) ligands and their uses | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| SG11202102335YA (en) | Anti-tnfrsf9 antibodies and uses thereof | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| SG11202105161YA (en) | Anti-il-27 antibodies and uses thereof | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| IL283890A (en) | Anti-periostin antibodies and their uses | |
| EP4063387A4 (en) | PSMA ANTIBODIES AND ITS USE |